FDA approves therapy to protect bone marrow cells from effects of chemotherapy
The U.S. Food and Drug Administration approved the first therapy in its class to reduce the frequency of bone marrow suppression induced by chemotherapy for extensive-stage small cell lung cancer, the agency announced Friday.